Table 3 |
||||||
|
The prevalence of triple mutations in Pfdhfr, double mutations in Pfdhps and quintuple mutations in Pfdhfr/Pfdhps in the two cross sectional surveys according to age |
||||||
| Pfdhfr triple MT |
Pfdhps double MT |
Pfdhfr and Pfdhps quintuple MT |
||||
|
|
||||||
| Age (years) |
Cross1 |
Cross2 |
Cross1 |
Cross2 |
Cross1 |
Cross2 |
|
|
||||||
| 1–5 |
4/12 (33.3) |
16/24 (66.7) |
2/12 (16.7) |
11/21 (52.4) |
1/10 (10.0) |
8/16 (50.0) |
| 6–14 |
20/43 (46.5) |
24/43 (55.8) |
7/46 (15.2) |
17/45 (37.8) |
1/31 (3.2) |
8/36 (22.2) |
| >14 |
22/44 (50.0) |
18/42 (42.9) |
7/46 (15.2) |
12/49 (24.5) |
4/34 (11.8) |
7/37 (18.9) |
|
|
||||||
| P = |
0.591 |
0.160 |
0.991 |
0.069 |
0.434 |
0.049 |
|
|
||||||
|
The donors are divided into 1–5 years, 6–14 years and above 14 years of age. Actual numbers of infections with Pfdhfr triple, Pfdhps double and Pfdhfr/Pfdhps quintuple mutations are shown out of total with the percentage of total in brackets. P: P-value of χ2-tests. |
||||||
|
Enosse et al. Malaria Journal 2008 7:115 doi:10.1186/1475-2875-7-115 |
||||||
